Nanotechnology refers broadly to a field of applied science and technology whose unifying theme is the control of matter on the molecular level in scales smaller than 1 micrometer, normally 1 to 100 nanometers, and the fabrication of devices within that size range. In the last five years this technology has been improved tremendously in disease diagnosis and prognosis and maximum research and clinical work has been completed in cancer.
Background
Nanomedicine is the medical application of nanotechnology. It covers areas such as nanoparticle drug delivery and possible future applications of molecular nanotechnology (MNT) and nanovaccinology (1) (2) (3) (4) . Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials. Some of the examples where nanotechnology shows promise include multifunctional nanoparticles for imaging and therapy (in diseases such as cancer), nanochannel implants for controlled release of drugs, nanoscale devices for evaluation of proteomics and genomics, and diagnostic techniques that take advantage of physical changes in diseased tissue (5, 6) . Recent advances in nanotechnology have made possible the design and development of tubular nanoscale particles called nanotubes (7) . The tubular shape of such particles is highly attractive since it is possible to differentially functionalize the inner and outer surfaces to facilitate drug loading, biocompatibility, and biorecognition. Novel synthetic strategies allow the fabrication of tubular structures with well-defined diameters and lengths. This can have important implications in biodistribution, subcellular trafficking, and drug release. Magnetic nanoparticles with appropriate surface coatings are increasingly being used clinically for various biomedical applications, such as magnetic resonance imaging, hyperthermia, drug delivery, tissue repair, cell, and tissue targeting and transfection. This is because of the nontoxicity and biocompatibility demand that mainly iron oxide-based materials are predominantly used, despite some attempts to develop 'more magnetic nanomaterials' based on cobalt, nickel, gadolinium, and other compounds.
The first use of the distinguishing concepts in 'nanotechnology' (but predating use of that name) was in "There's Plenty of Room at the Bottom," a talk given by physicist Richard Feynman at an American Physical Society meeting at Caltech on December 29, 1959. Feynman described a process by which the ability to manipulate individual atoms and molecules might be developed, using one set of precise tools to build and operate another proportionally smaller set, so on down to the needed scale. In the course of this, he noted, scaling issues would arise from the changing magnitude of various physical phenomena: gravity would become less important, surface tension and Van der Waals attraction would become more important, et cetera. This basic idea appears feasible, and exponential assembly enhances it with parallelism to produce a useful quantity of end products. The idea has been expanded tremendously in biomedical field.
Nanotechnology and nanoscience got started in the early 1980s with two major developments; the birth of cluster science and the invention of the scanning tunneling microscope (STM). This development led to the discovery of fullerenes in 1986 and carbon nanotubes a few years later. In another development, the synthesis and properties of semiconductor nanocrystals was studied. This led to a fast increasing number of metal oxide nanoparticles of quantum dots. The atomic force microscope was invented five years after the STM was invented. The AFM uses atomic force to see the atoms. Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.
In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g., bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity.
This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden. Recent developments in nanotechnology can address these challenges. In the following section we have discussed implication of nanotechnology and nanomedicine in cancer detection and treatment.
Nanotechnology in Cancer Diagnosis
Metallic nanoparticles conjugated to peptides have been prepared from Au and iron oxide (magnetic nanoparticles) (8). Several peptide-nanoparticle conjugates show biocompatibility and present a low degree of cytotoxicity. Furthermore, several peptide-metallic nanoparticle conjugates are used for in vitro diagnosis (2, 3).
Nanoparticles of cadmium selenide (quantum dots) glow when exposed to ultraviolet light. When injected, they seep into cancer tumors. The surgeon can see the glowing tumor, and use it as a guide for more accurate tumor removal.
Sensor test chips containing thousands of nanowires, able to detect proteins and other biomarkers left behind by cancer cells, could enable the detection and diagnosis of cancer in the early stages from a few drops of a patient's blood (9). Nanotechnology offers a wide range of tools, from chipbased nanolabs capable of monitoring and manipulating individual cells to nanoscale probes that can track the movements of cells, and even individual molecules, as they move about in their environment. Using such tools will enable cancer biologists to study, monitor, and alter the multiple systems that are implicated in cancer processes and identify key biochemical and genetic targets for future molecular therapies. As such, nanotechnology can complement other technology platforms, such as proteomics and bioinformatics. Another near-term application of nanotechnology to accelerate basic research is to use molecular-size nanoparticles with a wide range of optical properties (e.g., quantum dots) to track individual molecules or cells as they move through local environments, thereby monitoring multiplexed cellular and molecular events in real time. When combined with mouse models that reproduce the genetic, biochemical, and physiological properties of human cancers, these nanolabels will be useful for integrative, systems biology research. Finally, nanoscale devices that enable simultaneous biochemical measurements (e.g., time, size, dynamic events) on multiple cells, particularly those grown in such a way as to mimic tissue development in vivo, will bring new dimensionality to basic cancer research.
Nanotechnology is the popular term used for the construction and utilization of functional structures with at least one characteristic dimension measured on the nanometer scale. Because of the very small dimensions, most applications of nanobiotechnology in molecular diagnostics fall under the broad category of biochips/microarrays but can be more correctly termed nanochips and nanoarrays. Nanotechnology on a chip is a new paradigm for total chemical analysis systems on a nanoscale. One example of nanotechnology is the use of quantum dots, nanocrystals of cadmium selenide that are 200-to 10,000-atoms wide and coated with zinc sulfide. The size of the dot determines the frequency of light emitted when irradiated with low energy light. This spectral coding technology is expected to open new opportunities in gene expression studies, high throughput screening and medical diagnostics. The initial and most practically useful applications are expected in POC diagnostics where nanotechnology provides advantages over conventional nucleic acid based chips.
Nanotechnology in Imaging
A number of monodisperse magnetic nanoparticle preparations have been developed over the last decade for angiogenesis imaging, cancer staging, tracking of immune cells (monocyte/macrophage, T cells), and for molecular and cellular targeting (7, 10, 11). Further, the combination of newer nuclear imaging techniques providing high sensitivity and spatial resolution such as dual modality imaging with positron emission tomography/computed tomography (PET/CT) and use of nanoscale devices to carry diagnostic and therapeutic radionuclides with high target specificity can enable more accurate detection, staging and therapy planning of cancer (9).
Nanorods coated with cetyltrimethylammonium bromide (a cationic surfactant used in nanorod synthesis) are internalized within hours into cells by a nonspecific uptake pathway, whereas the careful removal of cetyltrimethylammonium bromide from nanorods functionalized with folate results in their accumulation on the cell surface over the same time interval. In either case, the nanorods render the tumor cells highly susceptible to photothermal damage when irradiated at the nanorods' longitudinal plasmon resonance, generating extensive blebbing of the cell membrane (12) . Researchers at Rice University have demonstrated the use of 120nm diameter nanoshells coated with gold to kill cancer tumors in mice. The nanoshells can be targeted to bond to cancerous cells by conjugating antibodies or peptides to the nanoshell surface. By irradiating the area of the tumor with an infrared laser, which passes through flesh without heating it, the gold is heated sufficiently to cause death to the cancer cells. Nanotechnology has also opened ways for the development of contrast agents and radiopharmaceuticals for specific targeting, which is presently changing research strategies in the field of magnetic resonance imaging, ultrasound imaging and nuclear medicine applications (11, 13) .
A growing body of research has demonstrated that gold nanorods can serve as extremely bright imaging agents. Now, by linking gold nanorods to an antibody that binds to tumor cells, researchers at the Georgia Institute of Technology have found that gold nanorods will align themselves in an ordered fashion on the surface of cancer cells, further intensifying the optical signal the nanorods produce and providing a unique optical signature for tumor cells. A team of investigators prepared gold nanoparticles linked to an antibody that binds the cell-surface receptor EGFR. When incubated with both normal cells and those from a human oral tumor and imaged using several different spectroscopic techniques, the gold nanorods produce a strong, sharp image only for the tumor cells. Indeed, the optical signal from tumor cells was twice as bright as from normal cells. The investigators suspect that this difference results from the gold nanoparticles becoming aligned with one another when bound to the tumor cell surface through their linked antibody; previous research has shown that EGFR molecules occur in clusters on the surfaces of many types of tumor cells. When aligned with one another, adjacent nanorods interact electronically in such as way as to boost their combined optical output. The investigators note that this output boost can serve as a molecular signature unique to tumor cells.
In the quest to turn carbon nanotubes from nanoscale wonder into clinically useful drug and imaging agent delivery agents, researchers have often added polymer coatings to the outside of the nanotubes in order to render them biocompatible. Now, researchers at Stanford University have found that even when coated, carbon nanotubes retain the ability to bind extraordinarily large numbers of drug and imaging agent molecules in a stable yet reversible manner. The Stanford researchers showed that polymer-coated single-walled carbon nanotubes spontaneously absorbed the cancer drug doxorubicin onto their surfaces when the drug was added to the nanotubes dissolved in water. The resulting construct contained approximately 50 to 60 percent doxorubicin by weight, far higher than the 8 to 10 percent obtained with either liposomes or dendrimers.
The investigators also found that the carbon nanotubes retained their drug payload when dissolved in normal physi- ological buffer and blood serum, but that the drug released quickly from the nanotubes in the acidic environment characteristic of the insides of tumor cells. The investigators showed, too, that they could permanently attach tumor-targeting molecules and imaging contrast agents to the nanotubes, raising the possibility of creating multifunctional nanoscale devices that could both detect and treat tumors.
Nanotechnology in Drug Delivery
Drug delivery systems, lipid-or polymer-based nanoparticles, can be designed to improve the pharmacological and therapeutic properties of drugs. The strength of drug delivery systems is their ability to alter the pharmacokinetics and biodistribution of the drug. Nanoparticles have unusual properties that can be used to improve drug delivery. Where larger particles would have been cleared from the body, cells take up these nanoparticles because of their size. Complex drug delivery mechanisms are being developed, including the ability to get drugs through cell membranes and into cell cytoplasm. Efficiency is important because many diseases depend upon processes within the cell and can only be impeded by drugs that make their way into the cell. Triggered response is one way for drug molecules to be used more efficiently.
Drugs are placed in the body and only activate on encountering a particular signal. For example, a drug with poor solubility will be replaced by a drug delivery system where both hydrophilic and hydrophobic environments exist, improving the solubility. Also, a drug may cause tissue damage, but with drug delivery, regulated drug release can eliminate the problem. If a drug is cleared too quickly from the body, this could force a patient to use high doses, but with drug delivery systems clearance can be reduced by altering the pharmacokinetics of the drug. Poor biodistribution is a problem that can affect normal tissues through widespread distribution, but the particulates from drug delivery systems lower the volume of distribution and reduce the effect on non-target tissue. Potential nanodrugs will work by very specific and well-understood mechanisms, one of the major impacts of nanotechnology and nanoscience will be in leading development of completely new drugs with more useful behavior and less side effects. Nanocarriers should be specifically delivered (targeted) to the pathological area to provide the maximum therapeutic efficacy. Among the many potential targets for such nanocarriers, tumors have been most often investigated. Certain issues related to some popular pharmaceutical nanocarriers, such as liposomes and polymeric micelles, are being investigated in different laboratories, as are different ways to target tumors via specific ligands and via the stimuli sensitivity of the carriers. The importance of intracellular targeting of drug-and DNA-loaded pharmaceutical nanocarriers is specifically significant, including intracellular delivery with cell-penetrating peptides.
Magnetic nanoparticles can bind to drugs and an external magnetic field can be applied to trap them in the target site. By attaching the targeting molecules, such as proteins or antibodies, at particles surfaces, the latter may be directed to any cell, tissue or tumor in the body. Some selected proteins/targeting ligands that could be used for derivatizing magnetic nanoparticles are also being explored. These approaches have potential to be used for early detection of cancer, diabetes, and atherosclerosis. Furthermore, these developments have opened exciting opportunities for personalized oncology in which cancer detection, diagnosis, and therapy are tailored to each individual's molecular profile, and also for predictive oncology, in which genetic/molecular information is used to predict tumor development, progression, and clinical outcome (14).
A nanoparticle drug delivery system designed for brain tumor therapy has shown promising tumor cell selectivity in a novel cell culture model devised by University of Nottingham scientists.The nanoparticles used in this study were prepared from a novel biodegradable polymer poly(glycerol adipate). The polymer has been further modified to enhance incorporation of drugs and make the nanoparticles more effective. To test the nanoparticles, the investigators developed a new in vitro system that should prove useful in a variety of brain cancer studies. Brain tumor cell aggregates were labeled with fluorescent iron microparticles and grown on normal newborn rat brain tissue slices. The double-cell labeling technique allowed investigation of tumor cell invasion into brain tissue by either fluorescence or electron microscopy from the same samples. Using these techniques, the tumor aggregates were found to invade the brain slices in a similar manner to tumors in the body.
Nanotechnology in Cancer Therapy and Prognosis
Several nanoscale carriers (nanoparticles, liposomes, water-soluble polymers, micelles, and dendrimers) have been developed for targeted delivery of cancer diagnostic and therapeutic agents. These carriers can selectively target cancer sites and carry large payloads, thereby improving cancer detection and therapy effectiveness (9). Nanodevices could be observed at work inside the body using MRI, especially if their components were manufactured using mostly 13 C atoms rather than the natural 12 C isotope of carbon, since 13 C has a nonzero nuclear magnetic moment. Medical nanodevices would first be injected into a human body, and would then go to work in a specific organ or tissue mass. The doctor will monitor the progress, and make certain that the nanodevices got to the correct target treatment region. The doctor wants to be able to scan a section of the body, and actually see the nanodevices congregated neatly around their target (a tumor mass, etc.) so that he or she can be sure that the procedure was successful. Tracking movement can help determine how well drugs are being distributed or how substances are metabolized. It is difficult to track a small group of cells throughout the body so scientists used to dye the cells. These dyes needed to be excited by light of a certain wavelength in order for them to light up. While different color dyes absorb different frequencies of light, there was a need for as many light sources as cells. A way around this problem is with luminescent tags. These tags are quantum dots attached to proteins that penetrate cell walls. The dots can be random in size, can be made of bio-inert material, and they demonstrate the nanoscale property that color is size-dependent. As a result, sizes are selected so that the frequency of light used to make a group of quantum dots fluoresce is an even multiple of the frequency required to make another group incandesce. Then both groups can be lit with a single light source.
In photodynamic therapy, which also utilizes nanotechnology, a particle is placed within the body and is illuminated with light from the outside. The light gets absorbed by the particle and if the particle is metal, energy from the light will heat the particle and surrounding tissue. Light may also be used to produce high energy oxygen molecules which will chemically react with and destroy most organic molecules that are next to them (like tumors). This therapy is appealing for many reasons. It does not leave a "toxic trail" of reactive molecules throughout the body (chemotherapy) because it is directed where only the light is shined and the particles exist. Photodynamic therapy has potential for a noninvasive procedure for dealing with diseases, growths, and tumors.
Photodynamic therapy, in which light activates a chemical known as a photosensitizer, triggering the production of cellkilling reactive oxygen, has proven itself as an effective therapy for a limited number of cancers. Oncologists have long suspected that photodynamic therapy could find broader use if only there was some way to limit the accumulation of photosensitizer molecules to tumors, sparing healthy tissue from unintended damage. Now, using modified silica nanoparticles, a team of investigators at the State University of New York, Buffalo, has developed a photosensitizer delivery method that has the potential to target tumor cells specifically (14).
The investigators found that human colon cancer cells readily take up the photosensitizer-loaded nanoparticles. More importantly, shining light on these cells resulted in their death. In contrast, cells that were not exposed first to these nanoparticles suffered no ill effects from exposure to light.
Challenges and Future Directions
In the fight against the pain, suffering, and death due to cancer, nanotechnology may allow prevention, earlier detection, diagnosis, and prognosis of cancer at premalignant stages, in addition to providing multimodality treatment not possible with current conventional techniques (4, 9) . The successful clinical applications of radiolabeled monoclonal antibodies for cancer detection and therapy bode well for the future of nanoscale carrier systems in clinical oncology. Several radiolabeled multifunctional nanocarriers have been effective in detecting and treating cancer in animal models. Nonetheless, further preclinical, clinical, and long-term toxicity studies will be required to translate this technology to the care of patients with cancer.
Superparamagnetic iron oxide nanoparticles (SPION) with appropriate surface chemistry have been widely used experimentally for numerous in vivo applications such as magnetic resonance imaging contrast enhancement, tissue repair, immunoassay, detoxification of biological fluids, hyperthermia, drug delivery, and in cell separation, et cetera. All these biomedical and bioengineering applications require that these nanoparticles have high magnetization values and size smaller than 100 nm with overall narrow particle size distribution, so that the particles have uniform physical and chemical properties. In addition, these applications need special surface coating of the magnetic particles, which has to be not only non-toxic and biocompatible but also allow a targetable delivery with particle localization in a specific area. To this end, most work in this field has been done in improving the biocompatibility of the materials, but only a few scientific investigations and developments have been carried out in improving the quality of magnetic particles, their size distribution, their shape and surface in addition to characterizing them to get a protocol for the quality control of these particles. Nature of surface coatings and their subsequent geometric arrangement on the nanoparticles determine not only the overall size of the colloid but also play a significant role in biokinetics and biodistribution of nanoparticles in the body, especially in cases where specific receptors are located on the outer surface of cells. The types of specific coating, or derivatization, for these nanoparticles depend on the end application and should be chosen by keeping a particular application in mind, whether it be aimed at inflammation response, vaccine efficacy, or anti-cancer agents. Magnetic nanoparticles can bind to drugs, proteins, enzymes, antibodies, or nucleotides and can be directed to an organ, tissue, or tumor using an external magnetic field or can be heated in alternating magnetic fields for use in hyperthermia.
In the near future, advancement in nanomedicine will deliver a valuable set of research tools and clinically helpful devices. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that will include advanced drug delivery systems, new therapies, and in vivo imaging. Farther down the line, neuro-electronic interfaces and cell repair machines, considering their application in brain tumors, could revolutionize medicine and the medical field, but now nanomedicine is becoming one of the biggest industries in the world. In 2004, nanomedicine sales reached 6.8 billion dollars, and with over 200 companies and 38 products worldwide, a minimum of 3.8 billion dollars in nanotechnology R&D is being invested every year. As the nanomedicine industry continues to grow, there is no doubt that it will have a significant impact on the economy. Here, it is emphasized that nanotechnology related information can be tested in one disease and then custom made for other diseases. The most important innovations are taking place in drug delivery, which involves developing nanoscale particles or molecules to improve bioavailability. Bioavailability refers to the presence of drug molecules where they are needed in the body and where they will do the most good. Drug delivery focuses on maximizing bioavailability both at specific places in the body and over a period of time. Over 65 billion dollars is wasted every year because of poor bioavailability. In vivo imaging is another area where tools and devices are being developed. Using nanoparticle contrast agents, images such as ultrasound and MRI have a favorable distribution and improved contrast. The new therapies and surgeries that are being developed might be effective in treating illnesses and diseases such as cancer. Finally, a shift from the possible to the potential will be made when nanorobots such as neuroelectronic interfaces and cell repair machines.
The potential applications of nanotechnology, most current commercialized applications are considered for the use of "first generation" passive nanomaterials. These include titanium dioxide nanoparticles in sunscreen, cosmetics, and some food products; silver nanoparticles in food packaging, clothing, disinfectants, and household appliances; zinc oxide nanoparticles in sunscreens and cosmetics, surface coatings, paints, and outdoor furniture varnishes; and cerium oxide nanoparticles as a fuel catalyst. The Woodrow Wilson Center for International Scholars' Project on Emerging Nanotechnologies hosts an inventory of consumer products that now contain nanomaterials. However, further applications that require actual manipulation or arrangement of nanoscale components await further research. Though technologies currently branded with the term 'nano' are sometimes little related to and fall far short of the most ambitious and transformative technological goals of the sort in molecular manufacturing proposals, the term still connotes such ideas. Thus, there may be a danger that a "nano bubble" will form, or is forming already, from the use of the term by scientists and entrepreneurs to garner funding, regardless of interest in the transformative possibilities of more ambitious and far-sighted work (15).
